Navigation Links
China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2008 Financial Results
Date:7/10/2008

US Dollars)

Three months ended March 31, Years ended March 31,

2008 2007 2008 2007

(unaudited) (unaudited)

Net sales 12,689,489 $8,376,788 $42,321,111 $30,609,941

Cost of sales (4,270,441) (2,390,986) (12,310,092) (8,910,633)

Gross profit 8,419,048 5,985,802 30,011,019 21,699,308

Operating expenses:

Selling expenses (1,873,372) (1,236,525) (6,869,109) (4,502,687)

General and

administrative expenses (1,670,930) (890,476) (4,826,473) (2,265,220)

Total operating expenses (3,544,302) (2,127,001) (11,695,582) (6,767,907)

Income from operations 4,874,746 3,858,801 18,315,437 14,931,401

Other income and

expenses:

Other income 3,973,432 81,159 4,163,438 223,401

Other expenses 404,147 26,528 -- (62,948)

Total other income

(expenses) 4,377,580 107,688 4,163,438 160,453

Income before taxes 9,252,326 $3,966,489 22,478,875 15,091,854

Provision for income

taxes (1,264,197) (1,120,756) (4,936,631) (4,186,868)

Net income 7,988,129 $2,845,733 17,542,244 $10,904,986

Earnings per share:

Basic $0.47 $0.17 $1.03 $0.64

Diluted $0.26 $0.17 $0.80 $0.64

Weighted average shares

outstanding:

Basic 17,080,000 17,080,000 17,080,000 17,080,000

Diluted 17,719,269 17,080,000 17,719,269 17,080,000

CHINA-BIOTICS, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

(Audited, amounts expressed in US Dollars)


'/>"/>

SOURCE China-Biotics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. China-Biotics, Inc. to Present at Chinas 3rd Annual Food Safety Technology Forum 2008
2. China-Biotics, Inc. Announces Conference Call to Discuss Fourth Quarter and Full Year 2008 Results
3. China-Biotics, Inc. to Supply Probiotics to Pharmaceutical Company
4. China-Biotics, Inc. to Present at Two Upcoming Investor Conferences
5. China-Biotics, Inc. Completes Foundation for Its New Plant
6. China-Biotics, Inc. Reports Third Quarter 2008 Financial Results
7. China-Biotics, Inc. Announces Rescheduling of Conference Call to Discuss Third Quarter 2008 Results
8. China-Biotics, Inc. Launches English / Chinese Corporate and Investor Relations Web Site
9. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter FY 2008 Results
10. China-Biotics, Inc. Receives Approval to Begin Construction on Large-Scale Manufacturing Facility
11. China-Biotics, Inc. Launches Shining Probiotics Protein Powder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... July 14, 2014 Throughout this ... across the clinical trials space, representing 38 countries ... series entitled “Optimizing Patient Participation in Clinical Trials. ... off with internationally renowned R&D expert, Ken Getz, ... on Reinventing Drug Development through Patient Centricity. , ...
(Date:7/14/2014)... Mass. , July 14, 2014 Minerva ... the development of new therapies to treat neuropsychiatric diseases ... has been appointed vice president of finance and ... Mr. Ahlholm is a senior executive with more than ... at technology and life science companies. His background includes ...
(Date:7/14/2014)... Mateo, CA (PRWEB) July 14, 2014 ... CONNECT patient registry platform, announced that three ... muscular dystrophies; the Phelan-McDermid Syndrome International Registry; ... Nephrotic Syndrome—have been awarded contracts by the ... of the creation of a new health ...
(Date:7/13/2014)... R.I. (Brown University) -- The discovery 30 years ago ... an explosion of nanotechnology research. Now, there appears to ... from Brown University, Shanxi University and Tsinghua University in ... atoms forms a hollow molecular cage similar to a ... boron cage structurepreviously only a matter of speculationdoes indeed ...
Breaking Biology Technology:Optimizing Patient Participation in Clinical Trials: Attract. Engage. Retain. – eCongress eBox Archives Now Available 2Optimizing Patient Participation in Clinical Trials: Attract. Engage. Retain. – eCongress eBox Archives Now Available 3Optimizing Patient Participation in Clinical Trials: Attract. Engage. Retain. – eCongress eBox Archives Now Available 4Optimizing Patient Participation in Clinical Trials: Attract. Engage. Retain. – eCongress eBox Archives Now Available 5Minerva Neurosciences Announces Appointment Of Frederick W. Ahlholm As VP Of Finance And Chief Accounting Officer 2PatientCrossroads Fuels Development of New National Clinical Research Network 2PatientCrossroads Fuels Development of New National Clinical Research Network 3Researchers discover boron 'buckyball' 2Researchers discover boron 'buckyball' 3
... (the,"Company") (OTC Bulletin Board: TBIO) today announced financial results ... results are,presented in the tables that follow. Second ... of $0.2 million or $0.00 per share,for the second ... of $0.4 million or,$0.01 per share for the second ...
... Mass., Aug. 14 Avitar, Inc. (OTC,Bulletin Board: AVTI) ... ended June 30, 2007. For the quarter ended ... operations compared to $1,202,000 from continuing,operations for the quarter ... amounted to $597,000 versus $696,000. The net income,was $301,000, ...
... -- China Medical,Technologies, Inc. (the "Company") (Nasdaq: ... develops, manufactures and markets advanced in-,vitro diagnostic products ... announced that it will participate in the Morgan,Stanley,s ... Kong Date: August 21, 2007 China ...
Cached Biology Technology:Transgenomic, Inc. Reports Second Quarter 2007 Results 2Transgenomic, Inc. Reports Second Quarter 2007 Results 3Transgenomic, Inc. Reports Second Quarter 2007 Results 4Transgenomic, Inc. Reports Second Quarter 2007 Results 5Transgenomic, Inc. Reports Second Quarter 2007 Results 6Transgenomic, Inc. Reports Second Quarter 2007 Results 7Transgenomic, Inc. Reports Second Quarter 2007 Results 8Avitar Reports Third Quarter Financial Results for Fiscal 2007 2Avitar Reports Third Quarter Financial Results for Fiscal 2007 3Avitar Reports Third Quarter Financial Results for Fiscal 2007 4
(Date:7/14/2014)... have shown how the main psychoactive ingredient in cannabis ... Research published today reveals the existence of previously unknown ... in shrinking tumours. , It is hoped that ... anti-cancer properties. , The research was co-led ... used samples of human breast cancer cells to induce ...
(Date:7/13/2014)... of more effective treatments for cachexia, a profound wasting ... all cancer patients, raising their risk of death, according ... have been tried to reverse the condition, which may ... treatments, but none have had great success. , Scientists ... Nature , led by Bruce Spiegelman, PhD, demonstrated ...
(Date:7/11/2014)... awarded Michael F. Holick, PhD, MD, of Boston University ... Avioli Award. Holick, a professor of medicine, physiology and ... understanding of vitamin D and its role in disease ... the American Society for Bone and Mineral Research (ASBMR) ... It is named for ASBMR,s first president and founding ...
Breaking Biology News(10 mins):UEA research reveals how cannabis compound could slow tumour growth 2Antibody halts cancer-related wasting condition 2Antibody halts cancer-related wasting condition 3BUSM's Michael F. Holick receives American Society for Bone and Mineral Research award 2
... a drink problem, there is a greater risk that you ... from the Sahlgrenska Academy, at the University of Gothenburg, Sweden. ... 50% more likely to have a drink problem in the ... new light on this link. Carried out by researcher Anna ...
... LAWRENCE University of Kansas scientists have found new evidence ... (LCPUFA) are good for developing brains and hearts. In ... of four formulas from birth to 12 months; three with ... formula with no LCPUFA, and tested at four, six and ...
... our understanding of genetics and biological processes in all animals, ... of animals, scientists are still finding the fruit fly to ... the University of Rochester. The latest revelation has to ... fruit flies. It was widely accepted that all X chromosomes ...
Cached Biology News:New thinking on regulation of sex chromosomes in fruit flies 2
... Serum; U.S. sourced, ideal for ... quality; Low hemoglobin; Endotoxin: < ... of US origin; U.S. sourced, ... an uncompromising quality. Low hemoglobin ...
Chicken polyclonal to ytzF ( Abpromise for all tested applications). Antigen: Full length protein...
Fetal Calf Serum Replacement (Bistec) serum...
...
Biology Products: